

# Building a Boolean model of signaling pathways altered in prostate cancer

Pauline Traynard<sup>1</sup>, Luis Tobalina<sup>2</sup>, David Henriques<sup>2</sup>, Emmanuel Barillot<sup>1</sup>, Julio Saez-Rodriguez<sup>2\*</sup>, Laurence Calzone<sup>1\*</sup>

1. Institut Curie, PSL Research University, Mines Paris Tech, Inserm, U900, Paris  
2. RWTH Aachen University, Faculty of Medicine, Joint Research Centre for Computational Biomedicine, MT12 Wendlingweg 2 D-52074 Aachen

pauline.traynard@curie.fr

## Introduction

The aim of this work is to build **Boolean models** to simulate specifically prostate cancer in individual patients or clones. That way, we seek to understand by which means the cells become cancerous and propose appropriate drug interventions to **personally treat** the patient.

This involves the following steps:


- build a **network of the signaling pathways** that include frequently altered genes in prostate cancer,
- identify **new molecular processes** to complement the network, in particular with **gene set quantification**, and **search detailed interactions** supported by literature relevant in these pathways,
- derive a **Boolean model** describing the network dynamics in specific contexts, and estimate **time evolution of phenotypic probabilities** with MaBoSS.

## PRECISE Personalized Engine for Cancer Integrative Study and Evaluation

This work is part of PrECISE, a project which studies prostate cancer and aims at:


- Elucidating clone-specific tumorigenic mechanisms
- Suggesting adequate therapeutic interventions based on personalized molecular and clinical information
- Validating these suggestions in prospective cohorts and a panel of prostatic cell lines
- Developing PrECISE into deployable software tool: user-friendly interface accessible to the clinical research community

www.precise-project.eu




## Building a regulatory map of prostate cancer

A published model [1] is extended using both pathway databases and the literature, and is made more specific to our cohort of patient data by applying gene set quantification methods.



Datasets (TCGA + PrECISE)

Significant pathways are identified from a predefined list of gene sets.




Pathway activity computed with ROMA from protein expression datasets in prostate samples

ROMA [2] is a gene set quantification tool that estimates pathway activity score and dispersion in multiple samples.

Hot spot (top contributing) genes are selected.

Example: BIRC5 top contributing gene in « death regulators »

Interactions linking novel nodes with the map are retrieved with Pypath.



Network built with Pypath, representing all neighbors of the novel node BIRC5 (blue) in Omnipath, with the nodes already included in the network colored in green

Pypath is a Python module for building molecular interaction networks. It is linked to Omnipath [3], a comprehensive collection of literature curated human signaling pathways.


## Dynamical model of prostate cancer

### - Building a logical model based on the regulatory map



The influence network is translated into a Boolean model. Each node can take two values 0 or 1 and is updated according to a logical rule associated to it, which takes into account the activity of its inputs. The inputs are linked with the logical operators AND, OR or NOT.

### - Stochastic simulations

From a set of initial conditions, the logical model is simulated stochastically using MaBoSS software. The solutions can be represented in different forms: a probability of network states equivalent to the asymptotic solutions of the stochastic simulations, or time evolution of the nodes of interest.



MaBoSS [4] is a probabilistic framework based on continuous time Markov chains, used to estimate time evolution of state probabilities in logical models.



## Prospects

### - Cell-specific data fitting

Phosphoproteomics data will be generated by PrECISE partners and used to automatically fit the model to cell types with CellNOpt [5].

### - Patient-specific model instantiation

The genetic profile of each patient can be encoded in the model as mutations or initial states. According to the initial conditions or altered genes, the probabilities of the phenotypes will vary and inform on the possible consequences of each modification on the cells.

### - Drug simulation

The effect of several drugs on the model can be simulated and compared to experimental observations. Predictions made under this framework are intrinsically accompanied by a mechanistic explanation and can provide a support to incorporate patient-specific molecular data.

## References

- [1] Fumia, H. F., & Martins, M. L. (2013). Boolean Network Model for Cancer Pathways: Predicting Carcinogenesis and Targeted Therapy Outcomes. PLoS ONE, 8(7)
- [2] Martignetti, L., Calzone, L., Bonnet, E., Barillot, E., & Zinovyev, A. (2016). ROMA: Representation and Quantification of Module Activity from Target Expression Data. Frontiers in Genetics, 7, 18.
- [3] Turei, D., Korcsmaros, T., Saez-Rodriguez, J.: Guidelines for literature curated signaling pathway resources (under revision)
- [4] Stoll, G., Viara, E., Barillot, E., Calzone, L. (2012). Continuous time Boolean modeling for biological signaling: application of Gillespie algorithm. BMC Syst Biol, 6:116.
- [5] C TerVe, T Cokelaer, A MacNamara, D Henriques, E Goncalves, MK Morris, M van Iersel, DA Lauffenburger, J Saez-Rodriguez. CellNOptR: a flexible toolkit to train protein signaling networks to data using multiple logic formalisms. BMC Systems Biology, 2012, 6:133

## Acknowledgements



The project PrECISE has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 668858.



## Tools

www.pypath.omnipathdb.org  
https://maboss.curie.fr  
https://github.com/sysbio-curie/Roma